Has Kenneth Gorson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $414,155 in general payments to Kenneth Gorson, MD across 126 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kenneth Gorson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kenneth Gorson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kenneth Gorson, MD

Neurology · Wellesley, MANPI 1275528192

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (54.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Argenx US, Inc. accounts for 64.3% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $266,556, 7.4 times the $36,010 reported in 2019. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$414,155in general payments, 2019–2025

Across 126 payments — averaging $3286.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Argenx US, Inc.$266K
Sanofi US Services Inc.$37K
Janssen Research & Development, LLC$36K
Pfizer$30K
UCB SA$20K
Sanofi$10K
plus $14K from 6 others

$9,390in research payments, 2019–2025

Across 6 payments — averaging $1565.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$9K

What the payments were for

Royalty or licence$225,00054%
Consulting fees$173,44942%
Speaking & faculty fees$14,0953%
Travel & lodging$1,0540%
Food & beverage$5580%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Argenx US, Inc.	18	$266,191
Sanofi US Services Inc.	13	$37,355
Janssen Research & Development, LLC	32	$36,212
Pfizer	21	$29,730
UCB SA	10	$19,845
Sanofi	11	$10,367
Shire North American Group Inc	12	$5,170
Takeda Pharmaceuticals U.S.A., Inc.	2	$3,604
Janssen Global Services, LLC	1	$2,475
Genentech, Inc.	4	$1,850
UCB GmbH	1	$1,300
Grifols Shared Services North America, Inc.	1	$57

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VYVGART$34,000
UCB7665$3,150
ERAXIS$300

How this compares

$414,155 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$221,504

Medicare patients

Services billed

32,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 46	13	$300,234
Dimethyl Fumarate	13	$8,620
Propranolol Hcl ErPropranolol Hcl	13	$1,581
Gabapentin	37	$1,388
Carbidopa-LevodopaCarbidopa/Levodopa	13	$1,322
Tramadol Hcl	33	$579
Baclofen	19	$563
Meclizine Hcl	20	$439
Primidone	11	$431
Venlafaxine Hcl ErVenlafaxine Hcl	12	$430
RizatriptanRizatriptan Benzoate	21	$410
Methadone Hcl	12	$315
Diclofenac Sodium ErDiclofenac Sodium	13	$283
Topiramate	20	$227
Prednisone	17	$165

Paid to pharmacies, not to this prescriber.

Other neurology in Wellesley

Joshua KatzWellesley$462K
Andrew BouleyWellesley$308K
Ellen LathiWellesley$90K
Christopher WrightBoston$2.5M
Shivang JoshiWestborough$1.2M
Egilius SpieringsWellesley Hills$680K
Thomas ScammellBoston$617K
Salvatore NapoliFoxboro$613K
Alfred SandrockBoston$490K
Guy BuckleBrookline$450K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →